XT
NTLA icon

XTX Topco’s Intellia Therapeutics NTLA Stock Holding History

XTX Topco’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$692K Buy
53,982
+9,219
+21% +$117K 0.01% 1734
2025
Q4 		$402K Buy
+44,763
New +$616K 0.01% 1813
2025
Q3 		– Sell
-41,639
Closed -$391K – 3046
2025
Q2 		$391K Sell
41,639
-39,258
-49% -$322K 0.02% 1273
2025
Q1 		$575K Buy
80,897
+36,989
+84% +$374K 0.03% 924
2024
Q4 		$512K Buy
43,908
+29,006
+195% +$453K 0.04% 753
2024
Q3 		$306K Sell
14,902
-35,562
-70% -$820K 0.02% 1166
2024
Q2 		$1.13M Buy
50,464
+32,201
+176% +$767K 0.1% 311
2024
Q1 		$502K Buy
18,263
+5,642
+45% +$157K 0.07% 484
2023
Q4 		$385K Sell
12,621
-2,255
-15% -$64.8K 0.08% 428
2023
Q3 		$470K Buy
+14,876
New +$577K 0.08% 439
2023
Q2 		– Sell
-13,258
Closed -$494K – 1701
2023
Q1 		$494K Buy
13,258
+55
+0.4% +$2.16K 0.1% 300
2022
Q4 		$461K Buy
13,203
+1,796
+16% +$85.4K 0.1% 340
2022
Q3 		$638K Buy
+11,407
New +$708K 0.16% 147
2021
Q3 		– Sell
-2,762
Closed -$447K – 945
2021
Q2 		$447K Buy
+2,762
New +$215K 0.15% 218

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco's NTLA Position: Q1 2026 in Review

XTX Topco increased its Intellia Therapeutics (NTLA) stake by 21% in Q1 2026, buying an estimated $117K and bringing the position to 53,982 shares worth $692K. The position accounts for 0.01% of the portfolio, ranked #1734.

XTX Topco first reported a position in NTLA in Q2 2021 and has held it in 14 quarters since. The position peaked at $1.13M in Q2 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • XTX Topco held 53,982 shares of Intellia Therapeutics worth $692K as of Q1 2026.
  • XTX Topco bought 9,219 Intellia Therapeutics shares in Q1 2026, an estimated $117K.
  • Intellia Therapeutics made up 0.01% of XTX Topco's portfolio in Q1 2026, its #1734 holding.
  • XTX Topco first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • XTX Topco's Intellia Therapeutics position peaked at $1.13M in Q2 2024.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.